Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481S |
| Therapy | Pirtobrutinib |
| Indication/Tumor Type | chronic lymphocytic leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | chronic lymphocytic leukemia | sensitive | Pirtobrutinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Jaypirca (pirtobrutinib) inhibited proliferation of patient-derived chronic lymphocytic leukemia cells harboring BTK C481S in culture (PMID: 36287227). | 36287227 |
| BTK C481S | chronic lymphocytic leukemia | sensitive | Pirtobrutinib | Case Reports/Case Series | Actionable | In a clinical case study, Jaypirca (pirtobrutinib) resulted in disease control lasting 7 months in a patient with chronic lymphocytic leukemia harboring BTK C481S (PMID: 39048721). | 39048721 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (36287227) | Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. | Full reference... |
| (39048721) | Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia. | Full reference... |